Punit Dhillon
Chief Executive Officer & Director Skye Biosciences
Punit Dhillon is CEO and Chairman of Nasdaq-listed biotech Skye Bioscience, entrepreneur and author. Skye’s lead candidate, nimacimab, a CB1 receptor inhibitor, is a Phase 2 stage clinical candidate in patients with obesity. Prior to Skye, Dhillon co-founded and led OncoSec Medical, raising over $200M and establishing partnerships with Merck and Genentech, and prior to that, served in several leadership roles at pharma companies. Dhillon co-founded YELL Canada, an accelerator program for high school students interested in business and entrepreneurship. He’s received several awards, including the Biocom Catalyst Award and BASS Alumni Community Impact Award. He holds a BA in political science with a minor in business administration from Simon Fraser University.
Seminars
- Demonstrating the potential of combination therapy utilizing a peripherally acting CB1 antagonist (namacimab) with semaglutide, as evidenced by recent data showing enhanced weight loss and strong efficacy results
- Mitigating CNS-mediated side effects by focusing on peripheral CB1 receptors in adipose and muscle tissue, establishing a path for long-term patient comfort and adherence that is critical to redefining the patient journey
- Defining the strategy for next-generation metabolic therapeutics that layer novel mechanisms onto incretin backbones to provide superior clinical outcomes and establish a more robust, long-term safety profile
